ID   ODP2_HUMAN              Reviewed;         647 AA.
AC   P10515; Q16783; Q53EP3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 3.
DT   07-APR-2021, entry version 237.
DE   RecName: Full=Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial;
DE            EC=2.3.1.12;
DE   AltName: Full=70 kDa mitochondrial autoantigen of primary biliary cirrhosis;
DE            Short=PBC;
DE   AltName: Full=Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex;
DE   AltName: Full=M2 antigen complex 70 kDa subunit;
DE   AltName: Full=Pyruvate dehydrogenase complex component E2;
DE            Short=PDC-E2;
DE            Short=PDCE2;
DE   Flags: Precursor;
GN   Name=DLAT; Synonyms=DLTA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-43; ALA-318 AND
RP   ASN-451.
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-647.
RC   TISSUE=Placenta;
RX   PubMed=3174635; DOI=10.1073/pnas.85.19.7317;
RA   Coppel R.L., McNeilage L.J., Surh C.D., van de Water J., Spithill T.W.,
RA   Whittingham S., Gershwin M.E.;
RT   "Primary structure of the human M2 mitochondrial autoantigen of primary
RT   biliary cirrhosis: dihydrolipoamide acetyltransferase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7317-7321(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 73-647, AND LIPOYLATION AT LYS-132 AND
RP   LYS-259.
RC   TISSUE=Liver;
RX   PubMed=3191998; DOI=10.1016/0014-5793(88)80337-5;
RA   Thekkumkara T.J., Ho L., Wexler I.D., Pon G., Liu T., Patel M.S.;
RT   "Nucleotide sequence of a cDNA for the dihydrolipoamide acetyltransferase
RT   component of human pyruvate dehydrogenase complex.";
RL   FEBS Lett. 240:45-48(1988).
RN   [5]
RP   SUBUNIT.
RX   PubMed=14638692; DOI=10.1074/jbc.m308172200;
RA   Hiromasa Y., Fujisawa T., Aso Y., Roche T.E.;
RT   "Organization of the cores of the mammalian pyruvate dehydrogenase complex
RT   formed by E2 and E2 plus the E3-binding protein and their capacities to
RT   bind the E1 and E3 components.";
RL   J. Biol. Chem. 279:6921-6933(2004).
RN   [6]
RP   INTERACTION WITH PDHB.
RX   PubMed=20160912; DOI=10.1016/j.molcatb.2009.05.001;
RA   Patel M.S., Korotchkina L.G., Sidhu S.;
RT   "Interaction of E1 and E3 components with the core proteins of the human
RT   pyruvate dehydrogenase complex.";
RL   J. Mol. Catal., B Enzym. 61:2-6(2009).
RN   [7]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-466, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-100, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   INTERACTION WITH SIRT4, LIPOYLATION AT LYS-132 AND LYS-259, AND
RP   DELIPOYLATION AT LYS-132 AND LYS-259.
RX   PubMed=25525879; DOI=10.1016/j.cell.2014.11.046;
RA   Mathias R.A., Greco T.M., Oberstein A., Budayeva H.G., Chakrabarti R.,
RA   Rowland E.A., Kang Y., Shenk T., Cristea I.M.;
RT   "Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex
RT   activity.";
RL   Cell 159:1615-1625(2014).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   STRUCTURE BY NMR OF 214-315.
RX   PubMed=9649469; DOI=10.1016/s0016-5085(98)70375-0;
RA   Howard M.J., Fuller C., Broadhurst R.W., Perham R.N., Tang J.G., Quinn J.,
RA   Diamond A.G., Yeaman S.J.;
RT   "Three-dimensional structure of the major autoantigen in primary biliary
RT   cirrhosis.";
RL   Gastroenterology 115:139-146(1998).
RN   [13]
RP   INVOLVEMENT IN PDHE2 DEFICIENCY.
RX   PubMed=16049940; DOI=10.1002/ana.20550;
RA   Head R.A., Brown R.M., Zolkipli Z., Shahdadpuri R., King M.D.,
RA   Clayton P.T., Brown G.K.;
RT   "Clinical and genetic spectrum of pyruvate dehydrogenase deficiency:
RT   dihydrolipoamide acetyltransferase (E2) deficiency.";
RL   Ann. Neurol. 58:234-241(2005).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=15861126; DOI=10.1038/sj.emboj.7600663;
RA   Kato M., Chuang J.L., Tso S.C., Wynn R.M., Chuang D.T.;
RT   "Crystal structure of pyruvate dehydrogenase kinase 3 bound to lipoyl
RT   domain 2 of human pyruvate dehydrogenase complex.";
RL   EMBO J. 24:1763-1774(2005).
RN   [15]
RP   STRUCTURE BY NMR OF 92-186.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-058, a lipoyl domain of human 2-oxoacid
RT   dehydrogenase.";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=17532006; DOI=10.1016/j.jmb.2007.04.083;
RA   Devedjiev Y., Steussy C.N., Vassylyev D.G.;
RT   "Crystal structure of an asymmetric complex of pyruvate dehydrogenase
RT   kinase 3 with lipoyl domain 2 and its biological implications.";
RL   J. Mol. Biol. 370:407-416(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 212-319 IN COMPLEX WITH PDK3.
RX   PubMed=17683942; DOI=10.1016/j.str.2007.07.001;
RA   Kato M., Li J., Chuang J.L., Chuang D.T.;
RT   "Distinct structural mechanisms for inhibition of pyruvate dehydrogenase
RT   kinase isoforms by AZD7545, dichloroacetate, and radicicol.";
RL   Structure 15:992-1004(2007).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 214-300 IN COMPLEX WITH PDK2.
RX   PubMed=18387944; DOI=10.1074/jbc.m800311200;
RA   Green T., Grigorian A., Klyuyeva A., Tuganova A., Luo M., Popov K.M.;
RT   "Structural and functional insights into the molecular mechanisms
RT   responsible for the regulation of pyruvate dehydrogenase kinase 2.";
RL   J. Biol. Chem. 283:15789-15798(2008).
RN   [19]
RP   STRUCTURE BY ELECTRON MICROSCOPY (18.3 ANGSTROMS) OF INNER CORE OF THE
RP   COMPLEX, AND SUBUNIT.
RX   PubMed=20361979; DOI=10.1016/j.jmb.2010.03.043;
RA   Vijayakrishnan S., Kelly S.M., Gilbert R.J., Callow P., Bhella D.,
RA   Forsyth T., Lindsay J.G., Byron O.;
RT   "Solution structure and characterisation of the human pyruvate
RT   dehydrogenase complex core assembly.";
RL   J. Mol. Biol. 399:71-93(2010).
CC   -!- FUNCTION: The pyruvate dehydrogenase complex catalyzes the overall
CC       conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the
CC       glycolytic pathway to the tricarboxylic cycle.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-N(6)-dihydrolipoyl-L-lysyl-[protein] + acetyl-CoA = (R)-
CC         N(6)-(S(8)-acetyldihydrolipoyl)-L-lysyl-[protein] + CoA;
CC         Xref=Rhea:RHEA:17017, Rhea:RHEA-COMP:10475, Rhea:RHEA-COMP:10478,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:83100,
CC         ChEBI:CHEBI:83111; EC=2.3.1.12;
CC   -!- COFACTOR:
CC       Name=(R)-lipoate; Xref=ChEBI:CHEBI:83088;
CC       Note=Binds 2 lipoyl cofactors covalently.;
CC   -!- SUBUNIT: Part of the multimeric pyruvate dehydrogenase complex that
CC       contains multiple copies of pyruvate dehydrogenase (subunits PDH1A and
CC       PDHB, E1), dihydrolipoamide acetyltransferase (DLAT, E2) and lipoamide
CC       dehydrogenase (DLD, E3) (PubMed:14638692). These subunits are bound to
CC       an inner core composed of about 48 DLAT and 12 PDHX molecules
CC       (PubMed:14638692, PubMed:20361979). Interacts with PDK2 and PDK3
CC       (PubMed:15861126, PubMed:17532006, PubMed:17683942, PubMed:18387944).
CC       Interacts with SIRT4 (PubMed:25525879). Interacts with PDHB
CC       (PubMed:20160912). {ECO:0000269|PubMed:14638692,
CC       ECO:0000269|PubMed:15861126, ECO:0000269|PubMed:17532006,
CC       ECO:0000269|PubMed:17683942, ECO:0000269|PubMed:18387944,
CC       ECO:0000269|PubMed:20160912, ECO:0000269|PubMed:20361979,
CC       ECO:0000269|PubMed:25525879}.
CC   -!- INTERACTION:
CC       P10515; P10515: DLAT; NbExp=2; IntAct=EBI-2959723, EBI-2959723;
CC       P10515; P11177: PDHB; NbExp=7; IntAct=EBI-2959723, EBI-1035872;
CC       P10515; Q15120: PDK3; NbExp=2; IntAct=EBI-2959723, EBI-1383915;
CC       P10515; Q9Y6E7: SIRT4; NbExp=6; IntAct=EBI-2959723, EBI-2606540;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- PTM: Delipoylated at Lys-132 and Lys-259 by SIRT4, delipoylation
CC       decreases the PHD complex activity. {ECO:0000269|PubMed:25525879}.
CC   -!- DISEASE: Note=Primary biliary cirrhosis is a chronic, progressive
CC       cholestatic liver disease characterized by the presence of
CC       antimitochondrial autoantibodies in patients' serum. It manifests with
CC       inflammatory obliteration of intra-hepatic bile duct, leading to liver
CC       cell damage and cirrhosis. Patients with primary biliary cirrhosis show
CC       autoantibodies against the E2 component of pyruvate dehydrogenase
CC       complex.
CC   -!- DISEASE: Pyruvate dehydrogenase E2 deficiency (PDHE2 deficiency)
CC       [MIM:245348]: Pyruvate dehydrogenase (PDH) deficiency is a major cause
CC       of primary lactic acidosis and neurological dysfunction in infancy and
CC       early childhood. In this form of PDH deficiency episodic dystonia is
CC       the major neurological manifestation, with other more common features
CC       of pyruvate dehydrogenase deficiency, such as hypotonia and ataxia,
CC       being less prominent. {ECO:0000269|PubMed:16049940}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 2-oxoacid dehydrogenase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA62253.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA62253.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK223596; BAD97316.1; -; mRNA.
DR   EMBL; AP000907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; J03866; AAA62253.1; ALT_SEQ; mRNA.
DR   EMBL; Y00978; CAA68787.1; -; mRNA.
DR   CCDS; CCDS8354.1; -.
DR   PIR; A40497; A40497.
DR   RefSeq; NP_001922.2; NM_001931.4.
DR   PDB; 1FYC; NMR; -; A=212-315.
DR   PDB; 1Y8N; X-ray; 2.60 A; B=212-319.
DR   PDB; 1Y8O; X-ray; 2.48 A; B=212-319.
DR   PDB; 1Y8P; X-ray; 2.63 A; B=212-319.
DR   PDB; 2DNE; NMR; -; A=92-186.
DR   PDB; 2PNR; X-ray; 2.50 A; C/G=212-319.
DR   PDB; 2Q8I; X-ray; 2.60 A; B=212-319.
DR   PDB; 3B8K; EM; 8.80 A; A=409-647.
DR   PDB; 3CRK; X-ray; 2.30 A; C/D=214-300.
DR   PDB; 3CRL; X-ray; 2.61 A; C/D=214-300.
DR   PDB; 6CT0; EM; 3.10 A; 0=1-647.
DR   PDB; 6H55; EM; 6.00 A; A=1-647.
DR   PDBsum; 1FYC; -.
DR   PDBsum; 1Y8N; -.
DR   PDBsum; 1Y8O; -.
DR   PDBsum; 1Y8P; -.
DR   PDBsum; 2DNE; -.
DR   PDBsum; 2PNR; -.
DR   PDBsum; 2Q8I; -.
DR   PDBsum; 3B8K; -.
DR   PDBsum; 3CRK; -.
DR   PDBsum; 3CRL; -.
DR   PDBsum; 6CT0; -.
DR   PDBsum; 6H55; -.
DR   SMR; P10515; -.
DR   BioGRID; 108081; 153.
DR   DIP; DIP-29496N; -.
DR   IntAct; P10515; 43.
DR   MINT; P10515; -.
DR   STRING; 9606.ENSP00000280346; -.
DR   DrugBank; DB03760; Dihydrolipoic Acid.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB03758; Radicicol.
DR   CarbonylDB; P10515; -.
DR   iPTMnet; P10515; -.
DR   PhosphoSitePlus; P10515; -.
DR   SwissPalm; P10515; -.
DR   BioMuta; DLAT; -.
DR   DMDM; 215274207; -.
DR   EPD; P10515; -.
DR   jPOST; P10515; -.
DR   MassIVE; P10515; -.
DR   PaxDb; P10515; -.
DR   PeptideAtlas; P10515; -.
DR   PRIDE; P10515; -.
DR   ProteomicsDB; 52610; -.
DR   ABCD; P10515; 1 sequenced antibody.
DR   Antibodypedia; 18282; 313 antibodies.
DR   DNASU; 1737; -.
DR   Ensembl; ENST00000280346; ENSP00000280346; ENSG00000150768.
DR   GeneID; 1737; -.
DR   KEGG; hsa:1737; -.
DR   CTD; 1737; -.
DR   DisGeNET; 1737; -.
DR   GeneCards; DLAT; -.
DR   HGNC; HGNC:2896; DLAT.
DR   HPA; ENSG00000150768; Tissue enhanced (heart).
DR   MalaCards; DLAT; -.
DR   MIM; 245348; phenotype.
DR   MIM; 608770; gene.
DR   neXtProt; NX_P10515; -.
DR   OpenTargets; ENSG00000150768; -.
DR   Orphanet; 79244; Pyruvate dehydrogenase E2 deficiency.
DR   PharmGKB; PA27350; -.
DR   VEuPathDB; HostDB:ENSG00000150768.15; -.
DR   eggNOG; KOG0557; Eukaryota.
DR   GeneTree; ENSGT00940000154943; -.
DR   InParanoid; P10515; -.
DR   OMA; TMEFESF; -.
DR   OrthoDB; 747232at2759; -.
DR   PhylomeDB; P10515; -.
DR   TreeFam; TF106145; -.
DR   BioCyc; MetaCyc:HS07688-MONOMER; -.
DR   BRENDA; 2.3.1.12; 2681.
DR   PathwayCommons; P10515; -.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   SABIO-RK; P10515; -.
DR   BioGRID-ORCS; 1737; 23 hits in 995 CRISPR screens.
DR   ChiTaRS; DLAT; human.
DR   EvolutionaryTrace; P10515; -.
DR   GeneWiki; Dihydrolipoyl_transacetylase; -.
DR   GenomeRNAi; 1737; -.
DR   Pharos; P10515; Tbio.
DR   PRO; PR:P10515; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P10515; protein.
DR   Bgee; ENSG00000150768; Expressed in heart and 246 other tissues.
DR   ExpressionAtlas; P10515; baseline and differential.
DR   Genevisible; P10515; HS.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005967; C:mitochondrial pyruvate dehydrogenase complex; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0045254; C:pyruvate dehydrogenase complex; IDA:UniProtKB.
DR   GO; GO:0004742; F:dihydrolipoyllysine-residue acetyltransferase activity; IDA:MGI.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0006086; P:acetyl-CoA biosynthetic process from pyruvate; IBA:GO_Central.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.559.10; -; 1.
DR   Gene3D; 4.10.320.10; -; 1.
DR   InterPro; IPR003016; 2-oxoA_DH_lipoyl-BS.
DR   InterPro; IPR001078; 2-oxoacid_DH_actylTfrase.
DR   InterPro; IPR000089; Biotin_lipoyl.
DR   InterPro; IPR023213; CAT-like_dom_sf.
DR   InterPro; IPR036625; E3-bd_dom_sf.
DR   InterPro; IPR006257; LAT1.
DR   InterPro; IPR004167; PSBD.
DR   InterPro; IPR011053; Single_hybrid_motif.
DR   Pfam; PF00198; 2-oxoacid_dh; 1.
DR   Pfam; PF00364; Biotin_lipoyl; 2.
DR   Pfam; PF02817; E3_binding; 1.
DR   SUPFAM; SSF47005; SSF47005; 1.
DR   SUPFAM; SSF51230; SSF51230; 2.
DR   TIGRFAMs; TIGR01349; PDHac_trf_mito; 1.
DR   PROSITE; PS50968; BIOTINYL_LIPOYL; 2.
DR   PROSITE; PS00189; LIPOYL; 2.
DR   PROSITE; PS51826; PSBD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Carbohydrate metabolism;
KW   Glucose metabolism; Lipoyl; Mitochondrion; Phosphoprotein;
KW   Reference proteome; Repeat; Transferase; Transit peptide;
KW   Tricarboxylic acid cycle.
FT   TRANSIT         1..86
FT                   /note="Mitochondrion"
FT   CHAIN           87..647
FT                   /note="Dihydrolipoyllysine-residue acetyltransferase
FT                   component of pyruvate dehydrogenase complex, mitochondrial"
FT                   /id="PRO_0000020479"
FT   DOMAIN          91..167
FT                   /note="Lipoyl-binding 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066"
FT   DOMAIN          218..294
FT                   /note="Lipoyl-binding 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066"
FT   DOMAIN          356..393
FT                   /note="Peripheral subunit-binding (PSBD)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01170"
FT   REGION          417..647
FT                   /note="Catalytic"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        620
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        624
FT                   /evidence="ECO:0000255"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         132
FT                   /note="N6-lipoyllysine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066,
FT                   ECO:0000269|PubMed:25525879, ECO:0000269|PubMed:3191998"
FT   MOD_RES         259
FT                   /note="N6-lipoyllysine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01066,
FT                   ECO:0000269|PubMed:25525879, ECO:0000269|PubMed:3191998"
FT   MOD_RES         466
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         473
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BMF4"
FT   MOD_RES         547
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BMF4"
FT   VARIANT         43
FT                   /note="A -> V (in dbSNP:rs2303436)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047410"
FT   VARIANT         98
FT                   /note="S -> F (in dbSNP:rs537057)"
FT                   /id="VAR_047411"
FT   VARIANT         99
FT                   /note="L -> F (in dbSNP:rs537060)"
FT                   /id="VAR_047412"
FT   VARIANT         209
FT                   /note="Q -> R (in dbSNP:rs11553595)"
FT                   /id="VAR_047413"
FT   VARIANT         313
FT                   /note="D -> V (in dbSNP:rs11553592)"
FT                   /id="VAR_047414"
FT   VARIANT         318
FT                   /note="V -> A (in dbSNP:rs627441)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047415"
FT   VARIANT         451
FT                   /note="D -> N (in dbSNP:rs10891314)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_047416"
FT   CONFLICT        112
FT                   /note="E -> K (in Ref. 4; CAA68787)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        342
FT                   /note="A -> T (in Ref. 3; AAA62253)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        358
FT                   /note="S -> D (in Ref. 3; AAA62253)"
FT                   /evidence="ECO:0000305"
FT   STRAND          92..95
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          100..102
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          105..110
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          123..129
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          134..138
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          140..147
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          156..158
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          162..168
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   HELIX           170..177
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          181..183
FT                   /evidence="ECO:0007744|PDB:2DNE"
FT   STRAND          218..222
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   STRAND          229..231
FT                   /evidence="ECO:0007744|PDB:1FYC"
FT   STRAND          232..238
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   STRAND          251..256
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   STRAND          261..265
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   STRAND          270..277
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   STRAND          283..285
FT                   /evidence="ECO:0007744|PDB:1Y8O"
FT   STRAND          289..297
FT                   /evidence="ECO:0007744|PDB:3CRK"
FT   HELIX           301..303
FT                   /evidence="ECO:0007744|PDB:2Q8I"
FT   HELIX           427..440
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          446..453
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           455..467
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          470..472
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           476..490
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           492..495
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          496..498
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          500..505
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          511..513
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   TURN            527..531
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           534..549
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           555..558
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          564..567
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   TURN            569..572
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          584..599
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          601..618
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   STRAND          620..622
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           625..640
FT                   /evidence="ECO:0007744|PDB:6CT0"
FT   HELIX           642..646
FT                   /evidence="ECO:0007744|PDB:6CT0"
SQ   SEQUENCE   647 AA;  68997 MW;  DD93A8E666E377C2 CRC64;
     MWRVCARRAQ NVAPWAGLEA RWTALQEVPG TPRVTSRSGP APARRNSVTT GYGGVRALCG
     WTPSSGATPR NRLLLQLLGS PGRRYYSLPP HQKVPLPSLS PTMQAGTIAR WEKKEGDKIN
     EGDLIAEVET DKATVGFESL EECYMAKILV AEGTRDVPIG AIICITVGKP EDIEAFKNYT
     LDSSAAPTPQ AAPAPTPAAT ASPPTPSAQA PGSSYPPHMQ VLLPALSPTM TMGTVQRWEK
     KVGEKLSEGD LLAEIETDKA TIGFEVQEEG YLAKILVPEG TRDVPLGTPL CIIVEKEADI
     SAFADYRPTE VTDLKPQVPP PTPPPVAAVP PTPQPLAPTP SAPCPATPAG PKGRVFVSPL
     AKKLAVEKGI DLTQVKGTGP DGRITKKDID SFVPSKVAPA PAAVVPPTGP GMAPVPTGVF
     TDIPISNIRR VIAQRLMQSK QTIPHYYLSI DVNMGEVLLV RKELNKILEG RSKISVNDFI
     IKASALACLK VPEANSSWMD TVIRQNHVVD VSVAVSTPAG LITPIVFNAH IKGVETIAND
     VVSLATKARE GKLQPHEFQG GTFTISNLGM FGIKNFSAII NPPQACILAI GASEDKLVPA
     DNEKGFDVAS MMSVTLSCDH RVVDGAVGAQ WLAEFRKYLE KPITMLL
//
